Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Geoffrey Weiss"'
Autor:
Mark E Smolkin, Gina R Petroni, Kimberly A Chianese-bullock, Kelly T Smith, Geoffrey Weiss, Nico Buettner, Mark Cobbold, Jeffrey Shabanowitz, Nikole Varhegyi, Elizabeth Gaughan, Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Angela L Ambakhutwala, Amanda Lulu, Paisley Myers, Keira E Mahoney, Emily H Hall, Kathleen Haden, Donald F Hunt, Craig L Slingluff, Jr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells. These peptides are promising targets for cancer immunotherapy. Previous work identified an HLA
Externí odkaz:
https://doaj.org/article/2f1ba13970c949eeb55d8d1382a456e4
Publikováno v:
The journal of pastoral carecounseling : JPCC. 72(2)
Approximately 5000 members of the Association of Professional Chaplains were surveyed using the Professional Quality of Life instrument in order to assess levels of Compassion Satisfaction and Compassion Fatigue and its associated subscales, Burnout
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e420d95c32197a59fc0bf730188b9733
https://pubmed.ncbi.nlm.nih.gov/29914332
https://pubmed.ncbi.nlm.nih.gov/29914332
Autor:
Abby B. Siegel, Vinay Duddalwar, Andie Edwards, Alan Brisendine, Elizabeth Garrett-Mayer, Melanie B. Thomas, Ari David Baron, Anthony B. El-Khoueiry, Geoffrey Weiss, Tricia A. Bentz, Johanna C. Bendell, Kate Anderton, Munazza Anis
Publikováno v:
Oncology
Objectives: To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Methods: A total of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346d1a8715bb07f0ab890a2c9d369565
https://pubmed.ncbi.nlm.nih.gov/29719302
https://pubmed.ncbi.nlm.nih.gov/29719302
Autor:
Josep Maria, Peralba, Linda, DeGraffenried, William, Friedrichs, Letitia, Fulcher, Viktor, Grünwald, Geoffrey, Weiss, Manuel, Hidalgo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(8)
CCI-779 is an ester of rapamycin and inhibitor of mammalian target of rapamycin (mTOR) currently in Phase II clinical development for the treatment of patients with cancer. CCI-779 interacts with mTOR and inhibits its kinase activity, resulting in in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ad297c9ba478dd96aa7fcf20e896127b
https://pubmed.ncbi.nlm.nih.gov/12912931
https://pubmed.ncbi.nlm.nih.gov/12912931
Autor:
Miguel A, Villalona-Calero, S Gail, Eckhardt, Geoffrey, Weiss, Manuel, Hidalgo, Jos H, Beijnen, Charlotte, van Kesteren, Hilde, Rosing, Elizabeth, Campbell, Maura, Kraynak, Luis, Lopez-Lazaro, Cecilia, Guzman, Daniel D, Von Hoff, Jose, Jimeno, Eric K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(1)
The purpose of this study was to (a) assess the feasibility of administering ecteinascidin-743 (ET-743), a novel DNA minor-groove disrupting agent of marine origin, administered as a daily i.v. infusion for 5 days every 3 weeks; (b) recommend a dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa9fd9d721b88ddf237b5c2575f4cf2c
https://pubmed.ncbi.nlm.nih.gov/11801542
https://pubmed.ncbi.nlm.nih.gov/11801542
Autor:
Johann S. de Bono, Joseph Stephenson, Sharyn D. Baker, Manuel Hidalgo, Amita Patnaik, Lisa A. Hammond, Geoffrey Weiss, Andrew Goetz, Lillian Siu, Cecelia Simmons, Jacques Jolivet, Eric K. Rowinsky
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(1)
PURPOSE: To assess the feasibility of administering troxacitabine, a unique l-nucleoside that is not a substrate for deoxycytidine deaminase–mediated catabolism, as a 30-minute intravenous (IV) infusion daily for 5 days. PATIENTS AND METHODS: Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2352f3cb5a66bde77b31f92f9d44dde3
https://pubmed.ncbi.nlm.nih.gov/11773159
https://pubmed.ncbi.nlm.nih.gov/11773159
Autor:
James G Wall, Howard A Burris, Daniel D Von Hoff, Gladys Rodriguez, Rayna Kneuper-Hall, Don Shaffer, Timothy OʼRourke, Thomas Brown, Geoffrey Weiss, Gary Clark, Shirley McVea, Randall Johnson, Carl Friedman, Brian Smith, William S Mann, John Kuhn
Publikováno v:
Anti-cancer drugs. 3(4)
Topotecan (SKF 104864) is a novel antitumor agent whose mechanism of action is inhibition of the DNA unwinding protein topoisomerase I. An analog of camptothecin, topotecan was designed to be more water soluble in an effort to decrease the severe and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2c9a269ff0c92cb2835d8dbd66ccfa
https://pubmed.ncbi.nlm.nih.gov/1330081
https://pubmed.ncbi.nlm.nih.gov/1330081
Publikováno v:
Medical Oncology; Dec2003, Vol. 20 Issue 4, p403-408, 6p
Publikováno v:
The Journal of Organic Chemistry. 36:2186-2188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c56baf63aa22400cd808e4dfd3dc0bd0
https://doi.org/10.1021/jo00814a035
https://doi.org/10.1021/jo00814a035
Autor:
Sosman, J. A., Aronson, F. R., Sznol, M., Atkins, M. B., Dutcher, J. P., Geoffrey Weiss, Isaacs, R. E., Margolin, K. A., Fisher, R. I., Ernest, M. L., Mier, J., Oleksowicz, L., Eckhardt, J. R., Levitt, D., Doroshow, J. H.
Publikováno v:
Scopus-Elsevier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::570ab540a34b4efc75d3cf812cd8c6e5
http://www.scopus.com/inward/record.url?eid=2-s2.0-0031042926&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0031042926&partnerID=MN8TOARS
